3-Mercaptopyruvic acid

3-Mercaptopyruvic acid
Names
	Preferred IUPAC name 2-Oxo-3-sulfanylpropanoic acid
	Other names 3-Mercapto-2-oxopropanoic acid; 3-MPV; 3-MP
Identifiers
CAS Number	2464-23-5 ;
3D model (JSmol)	Interactive image; Interactive image;
ChEBI	CHEBI:16208 ;
ChemSpider	96 ;
IUPHAR/BPS	5118;
KEGG	C00957 ;
MeSH	3-mercaptopyruvic+acid
PubChem CID	98;
UNII	5Z1F5OW4YB ;
CompTox Dashboard (EPA)	DTXSID20862960 DTXSID30947575, DTXSID20862960 ;
	InChI InChI=1S/C3H4O3S/c4-2(1-7)3(5)6/h7H,1H2,(H,5,6) Key: OJOLFAIGOXZBCI-UHFFFAOYSA-N ; InChI=1/C3H4O3S/c4-2(1-7)3(5)6/h7H,1H2,(H,5,6) Key: OJOLFAIGOXZBCI-UHFFFAOYAZ;
	SMILES C(C(=O)C(=O)O)S; O=C(O)C(=O)CS;
Properties
Chemical formula	C3H4O3S
Molar mass	120.12 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). verify (what is ?) Infobox references

3-Mercaptopyruvic acid is an intermediate in cysteine metabolism. It has been studied as a potential treatment for cyanide poisoning, but its half-life is too short for it to be clinically effective.^[1] Instead, prodrugs, such as sulfanegen, are being evaluated to compensate for the short half-life of 3-mercaptopyruvic acid.^[2]

References

^ Nagahara, N; Li, Q; Sawada, N (2003). "Do antidotes for acute cyanide poisoning act on mercaptopyruvate sulfurtransferase to facilitate detoxification?". Current Drug Targets. Immune, Endocrine and Metabolic Disorders. 3 (3): 198–204. doi:10.2174/1568008033340162. PMID 12871026.
^ Brenner, M; Kim, JG; Lee, J; Mahon, SB; Lemor, D; Ahdout, R; Boss, GR; Blackledge, W; Jann, L; Nagasawa, HT; Patterson, SE (2010). "Sulfanegen sodium treatment in a rabbit model of sub-lethal cyanide toxicity". Toxicology and Applied Pharmacology. 248 (3): 269–76. doi:10.1016/j.taap.2010.08.002. PMC 3382974. PMID 20705081.

This article about an organic compound is a stub. You can help Wikipedia by expanding it.

[1] Nagahara, N; Li, Q; Sawada, N (2003). "Do antidotes for acute cyanide poisoning act on mercaptopyruvate sulfurtransferase to facilitate detoxification?". Current Drug Targets. Immune, Endocrine and Metabolic Disorders. 3 (3): 198–204. doi:10.2174/1568008033340162. PMID 12871026.

[2] Brenner, M; Kim, JG; Lee, J; Mahon, SB; Lemor, D; Ahdout, R; Boss, GR; Blackledge, W; Jann, L; Nagasawa, HT; Patterson, SE (2010). "Sulfanegen sodium treatment in a rabbit model of sub-lethal cyanide toxicity". Toxicology and Applied Pharmacology. 248 (3): 269–76. doi:10.1016/j.taap.2010.08.002. PMC 3382974. PMID 20705081.

[1]

[2]

See also

References